Stockreport

Protara: A Bombed Out Biotech With A Very Positive Skew [Seeking Alpha]

Protara Therapeutics, Inc.  (TARA) 
PDF The company's main candidate, TARA-002, is being tested in phase 2 trials for NMIBC and lymphangiomas, with preliminary results expected in H1 2024. Protara is tradin [Read more]